Standout Papers

Nivolumab plus ipilimumab or nivolum... 2005 2026 2012 2019 4.2k
  1. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (2018)
    F. Stephen Hodi, Vanna Chiarion‐Sileni et al. The Lancet Oncology
  2. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer (2005)
    Frances A. Shepherd, José Rodrigues Pereira et al. New England Journal of Medicine
  3. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study (2009)
    Jedd D. Wolchok, Bart Neyns et al. The Lancet Oncology

Immediate Impact

25 by Nobel laureates 2 from Science/Nature 167 standout
Sub-graph 1 of 14

Citing Papers

Cutaneous melanoma
2023 Standout
Immune checkpoint inhibitors in melanoma
2021 Standout
48 intermediate papers

Works of Michael Smylie being referenced

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
2019
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
2018 Standout
and 8 more

Author Peers

Author Last Decade Papers Cites
Michael Smylie 7094 2396 1587 4305 92 8.9k
Leena Gandhi 5736 2672 1786 4042 143 8.5k
Daniil Stroyakovskiy 6933 2492 1327 3589 109 8.3k
Joo-Hang Kim 8190 3050 1374 6612 145 11.4k
Sinéad Cuffe 8340 1723 1839 5706 99 10.7k
Tibor Csőszi 8820 1232 1883 5714 81 10.4k
Reshma Rangwala 6851 1392 1768 4324 40 8.9k
Marcin Kowanetz 9158 2794 2548 5621 106 11.9k
Alan B. Sandler 4405 2405 628 3602 107 7.4k
Theodore F. Logan 4477 3274 2099 3187 118 7.9k
Hossein Borghaei 6996 1315 1833 4499 255 8.8k

All Works

Loading papers...

Rankless by CCL
2026